Chiesi Email Format

Pharmaceutical Manufacturing
5,001-10,000 employees
Parma, Emilia-Romagna, Italy

Chiesi is an international biopharmaceutical company that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care worldwide.

Find contacts at Chiesi

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@chiesi.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
1935
Headquarters
Parma, Emilia-Romagna, Italy
Revenue
$2.5B-$5B
FUNDING Stage
Private
Key Executives
Jean-Marc Bellemin (Interim Group CEO), Stefano Brandinali (Vice President e Chief Information and Technology Officer)

Tech Stack

Snowflake

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Chiesi?

Chiesi uses the first.last format, so Jane Smith would be jane.smith@chiesi.com.

What are Chiesi's three main therapeutic areas?

Chiesi organizes its business around three therapeutic areas: Air (respiratory health), Rare (rare diseases, managed through Chiesi Global Rare Diseases), and Care (specialty care). Together these three franchises drove the group's revenue growth in 2026.

How many countries does Chiesi operate in?

Chiesi operates through 31 affiliates worldwide, with a particularly strong presence in Europe, the United States, China, and emerging markets. The U.S. has been the group's fastest-growing region, with double-digit growth across recent years.

Where is Chiesi headquartered and who is its current CEO?

Chiesi is headquartered in Parma, Italy. Jean-Marc Bellemin serves as Interim Group CEO in 2026, supported by a senior leadership team that includes Chief Information and Technology Officer Stefano Brandinali.

Does TRIMBOW, Chiesi's triple inhaled therapy, have FDA approval?

Yes, TRIMBOW received FDA approval in May 2026 as a single-inhaler triple therapy for asthma maintenance in adults. The product is already commercialized in around 50 countries including EU markets, the UK, and China. You can use Clay to find Chiesi contacts in the respiratory division for outreach around this launch.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles